Natco Pharma secures USFDA nod for Trabectedin for Injection

Published On 2022-08-18 05:53 GMT   |   Update On 2022-08-18 05:53 GMT
Advertisement

Hyderabad: Drugmaker, Natco Pharma Limited has recently announced that the U.S. Food and Drug Administration (USFDA) has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection for the 1mg/vial presentation. The product is the generic version of cancer medicine Yondelis.

Yondelis is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Advertisement

According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.

Medical Dialogues team had earlier reported that the U.S. Food and Drug Administration (USFDA) had granted approval to its partner Breckenridge Pharmaceutical Inc's Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength used for the treatment of prostate cancer.

Read also: Natco partner bags USFDA nod for Cabazitaxel Intravenous Powder

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc

Read also: Natco Pharma reports multifold rise in net profit to Rs 320.4 crore in Q1

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News